In vitro activity of GAR-936 against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae

Robin Patel, Mark S. Rouse, Kerryl E. Piper, James M. Steckelberg

Research output: Contribution to journalArticle

49 Scopus citations


We report the activity of the new glycylcycline antimicrobial agent GAR-936 against 37 clinical isolates of vancomycin-resistant enterococci (including organisms carrying the vanA, vanB, vanC-1, and vanC-2/3 genes), 26 clinical isolates of methicillin-resistant S. aureus and 30 clinical isolates of high-level penicillin-resistant S. pneumoniae. All isolates of vancomycin-resistant enterococci, methicillin-resistant S. aureus, and penicillin-resistant S. pneumoniae were inhibited by ≤ 1, ≤ 2, or ≤ 0.25 μg/ml of GAR-936, respectively. Time kill experiments using vancomycin-resistant enterococci did not demonstrate synergy or antagonism between 2 μg/ml of GAR-936 and 0.25 μg/ml of quinupristin/dalfopristin. (C) 2000 Elsevier Science Inc.

Original languageEnglish (US)
Pages (from-to)177-179
Number of pages3
JournalDiagnostic Microbiology and Infectious Disease
Issue number3
StatePublished - Dec 12 2000


ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Cite this